nach oben

Journal of Neuro-Oncology

Erschienen in:

01.06.2012 | Methods and Clinical Tools for Outcome Assessments

Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies

verfasst von: Fabio Efficace, Martin Taphoorn

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Health-related quality of life (HRQOL) and other types of patient-reported outcomes (PROs) are now important outcome measures in cancer clinical trials. A number of potentially less toxic drugs are available, and newer treatments can potentially offer cancer patients the possibility to be treated with less aggressive approaches, making PROs more critical in evaluating treatment effectiveness. However, assessing PROs in clinical trials requires careful consideration of a number of methodological issues. Robust methodology and accurate reporting of results are crucial to provide the scientific community and health care providers with a transparent message about the impact of a given drug or a new medical approach on patients’ health status. This paper provides basic guidance on methodological issues to be addressed when designing and reporting HRQOL in clinical trials and presents examples of relevant brain cancer studies.

Moher D, Jones A, Lepage L (2001) Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 285:1992–1995PubMedCrossRef

Portney LG, Watkins MP (eds) (2000) Foundations of clinical research: applications to practice. Prentice Hall, Upper Saddle River

Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616PubMed

Schumacher M, Olschewski M, Schulgen G (1991) Assessment of quality of life in clinical trials. Stat Med 10:1915–1930PubMedCrossRef

Osoba D (2007) Translating the science of patient-reported outcomes assessment into clinical practice. J Natl Cancer Inst Monogr 37:5–11PubMedCrossRef

US Food and Drug Administration (2009) Guidance for industry. patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 13 Feb 2012

Bottomley A, Therasse P (2002) Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 3:620–628PubMedCrossRef

Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai S (2003) Health-related quality of life in non small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 21:2982–2992PubMedCrossRef

Efficace F, Bottomley A, Vanvoorden V, Blazeby JM (2004) Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials. Eur J Cancer 40:187–197PubMedCrossRef

10.

Efficace F, Bottomley A, van Andel G (2003) Health-related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 97:377–388PubMedCrossRef

11.

Fitzpatrick R, Davey C, Buxton MJ et al (1998) Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 2:1–74PubMed

12.

Fayers P, Hays R (2005) Assessing quality of life in clinical trials. Oxford University Press, New York

13.

de Haes J, Curran D, Young T, Bottomley A, Flechtner H, Aaronson N, Blazeby J, EORTC Quality of Life Study Group (2000) Quality of life evaluation in oncological clinical trials–the EORTC model. Eur J Cancer 36:821–825PubMedCrossRef

14.

Fayers PM, Hopwood P, Harvey A et al (1997) Quality of life assessment in clinical trials–guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer 33:20–28PubMedCrossRef

15.

Sloan J, Symonds T, Vargas-Chanes D et al (2003) Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 37:23–32CrossRef

16.

Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed

17.

Gotay CC, Korn EL, McCabe MS et al (1992) Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 84:575–579PubMedCrossRef

18.

Chassany O, Sagnier P, Marquis P et al (2002) Patient-reported outcomes: the example of health related quality of life-a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process. Drug Inf J 36:209–238CrossRef

19.

Efficace F, Bottomley A, Osoba D et al (2003) Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision-making? J Clin Oncol 21:3502–3511PubMedCrossRef

20.

Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A (2007) Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 18:775–781PubMedCrossRef

21.

Cocks K, King MT, Velikova G et al (2008) Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 44:1793–1798PubMedCrossRef

22.

van Meerbeeck JP, Gaafar R, Manegold C et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881–6889PubMedCrossRef

23.

Blazeby JM, Avery K, Sprangers M et al (2006) Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 24:3178–3186PubMedCrossRef

24.

Taphoorn MJ, Sizoo EM, Bottomley A (2010) Review on quality of life issues in patients with primary brain tumors. Oncologist 15:618–626PubMedCrossRef

25.

Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104:639–646PubMedCrossRef

26.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

27.

Brandsma D, van den Bent MJ (2007) Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 19:598–605PubMedCrossRef

28.

Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6:937–944PubMedCrossRef

29.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef

30.

Taphoorn MJ, Claassens L, Aaronson NK et al (2010) An international validation study of the EORTC brain cancer module (EORTC QLQ BN-20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46:1033–1040PubMedCrossRef

31.

Weitzner MA, Meyers CA, Gelke CK et al (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151–1161PubMedCrossRef

32.

Armstrong TS, Mendoza T, Gring I et al (2006) Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). J Neurooncol 80:27–35PubMedCrossRef

33.

Armstrong TS, Gring I, Mendoza T et al (2009) Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manag 37:331–340CrossRef

34.

Sneeuw KC, Sprangers MA, Aaronson NK (2002) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol 55:1130–1143PubMedCrossRef

35.

Brown PD, Decker PA, Rummans TA et al (2008) A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol 31:163–168PubMedCrossRef

36.

Taphoorn MJ, van den Bent MJ, Mauer ME et al (2007) Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 25:5723–5730PubMedCrossRef

37.

Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMedCrossRef

38.

van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRef

39.

Velikova G, Awad N, Coles-Gale R et al (2008) The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology 17:690–698PubMedCrossRef

40.

Mauer M, Taphoorn MJB, Bottomley A et al (2007) The prognostic value of health-related quality of life data in predicting survival in anaplastic oligodendrogliomas cancer patients: results from an international randomized phase III EORTC Brain Cancer Group study. J Clin Oncol 25:5731–5737PubMedCrossRef

41.

Mauer M, Stupp R, Taphoorn MJ et al (2007) The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumor and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer 97:302–307PubMedCrossRef

Titel: Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies
verfasst von: Fabio Efficace
Martin Taphoorn
Publikationsdatum: 01.06.2012
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0819-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Investigation of cognitive impairments in people with brain tumors

Refining endpoints in brain tumor clinical trials

Agnosias: recognition disorders in patients with brain tumors

Memory disorders in patients with cerebral tumors

Measuring clinical outcomes in neuro-oncology. A battery to evaluate low-grade gliomas (LGG)

Lessons from traumatic head injury for assessing functional status after brain tumour